heart failure/protease

BACKGROUND Despite significant advancements in high blood pressure (hypertension) medicines and the recognition that hypertension is a significant risk factor for the development of heart failure, this condition remains a major cardiovascular disease in the United States. One particular problem with

FIELD The present invention relates generally to treatment of contractile failure of the heart. More particularly, the present invention relates to the treatment of right ventricular (RV) contractile failure. In addition, this invention also relates to materials, methods and treatments for the

The Sequence Listing submitted Dec. 4, 2012 as a text file named "MUSC.sub.--10.sub.--8403_ST25.txt," created on Dec. 3, 2012, and having a size of 1,266 bytes is hereby incorporated by reference. BACKGROUND An important structural event following myocardial infarction (MI) is LV remodeling which

TECHNICAL FIELD The present invention relates to novel compounds and compositions which inhibit renin, processes for making such compounds, synthetic intermediates employed in these processes and a method of treating hypertension or congestive heart failure with such compounds or in combination with

The present invention relates to compounds of the formula I, ##STR00002## wherein A, D, E, G, R.sup.10, R.sup.11, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are

The present invention relates to compounds of the formula I, ##STR00002## wherein A, D, E, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for

This application claims the benefit of European Application No. EP13305402.3, filed Mar. 28, 2013, the disclosure of which is herein incorporated by reference in its entirety. The present invention relates to compounds of the formula I, ##STR00002## wherein X, R, R1, R2, D, E.sub.1, E.sub.2,

This application claims the benefit of European Application No. EP13305401.5, filed Mar. 28, 2013, the disclosure of which is herein incorporated by reference in its entirety. The present invention relates to compounds of the formula I, ##STR00002## wherein X, R, R1, R2, D, E.sub.1, E.sub.2,

The present invention relates to compounds of the formula I, ##STR00002## wherein Ht, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the

The present invention relates to compounds of the formula I, ##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful

The present invention relates to compounds of the formula I, ##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful

The present invention relates to compounds of the formula I, ##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful

The present invention relates to compounds of the formulae Ia and Ib, ##STR00002## wherein R1, R2, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are